Sensus Healthcare (NASDAQ:SRTS) Rating Lowered to “Strong Sell” at Zacks Research

Sensus Healthcare (NASDAQ:SRTS) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Sunday, June 22nd. Lake Street Capital reduced their target price on Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, HC Wainwright lowered their price target on Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS opened at $3.16 on Tuesday. The stock has a market capitalization of $51.95 million, a PE ratio of -52.67 and a beta of 1.41. Sensus Healthcare has a fifty-two week low of $3.03 and a fifty-two week high of $9.33. The business has a fifty day moving average price of $3.85 and a two-hundred day moving average price of $4.38.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07). The company had revenue of $7.32 million during the quarter, compared to analyst estimates of $9.30 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. On average, equities analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Kingstone Capital Partners Texas LLC acquired a new stake in Sensus Healthcare in the second quarter valued at $3,170,000. Divisadero Street Capital Management LP grew its position in shares of Sensus Healthcare by 459.4% in the 2nd quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company’s stock valued at $1,539,000 after buying an additional 266,635 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Sensus Healthcare by 35.3% in the first quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock valued at $2,225,000 after buying an additional 122,746 shares during the period. Pacific Ridge Capital Partners LLC bought a new position in shares of Sensus Healthcare during the first quarter worth about $542,000. Finally, Meros Investment Management LP acquired a new position in shares of Sensus Healthcare in the first quarter worth approximately $419,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.